炎症性肠病中的蛋白质活性:从肠道微生物群的洞察力
Jun-Jie Hou1, Liang Ding1, Tao Yang1
1Department of Gastroenterology, Shaoxing People's Hospital, Shaoxing, PR China.
Microbial pathogenesis
|January 25, 2024
概括
改变的肠道微生物群和增加的蛋白质分解活性 (PA) 与炎症性肠病 (IBD) 有关. 了解这种联系为IBD和其他消化系统疾病提供了新的诊断和治疗点.
科学领域:
- 胃肠道学和微生物学
- 专注于肠道微生物组与炎症性肠道疾病 (IBD) 中的蛋白质分解活性之间的复杂相互作用.
背景情况:
- 炎症性肠病 (IBD) 是一种慢性疾病,其特征是肠粘膜炎症.
- 肠道功能失调和失调的蛋白质分解越来越被认为是IBD病变的关键因素.
- 研究表明,IBD患者的肠道微生物群组成发生变化,蛋白质分解活性 (PA) 增加.
研究的目的:
- 探索蛋白质分解活性和微生物群衍生的蛋白质分解在IBD中的作用.
- 根据这些因素,确定IBD的潜在诊断和治疗点.
主要方法:
- 对肠道微生物群和IBD中的蛋白质分解活性进行现有研究的审查和综合.
- 从IBD患者的各种生物样本 (血清,血,粘膜,便) 中分析蛋白质分解活性.
主要成果:
- 在IBD中观察到肠道微生物群组成和多样性的持续变化.
- 在IBD患者的多种样本类型中检测到较高的蛋白质分解活性.
- 越来越多的证据表明,肠道微生态失衡,蛋白质水解和IBD之间存在重要联系.
结论:
- 蛋白质分解活性,特别是来自微生物群的酶,在IBD中起着至关重要的作用.
- 这些发现为IBD提供了新的诊断标记和治疗策略.
- 潜在的应用扩展到其他消化系统和蛋白酶相关疾病.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Inflammatory Bowel Disease I: Ulcerative Colitis
186
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
186
Inflammatory Bowel Disease II: Crohn's Disease
244
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
244
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Irritable Bowel Syndrome I: Introduction
276
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
276


